Diphencyprone and anthralin in alopecia areata
Phase 3
Recruiting
- Conditions
- alopecia areata.Alopecia areata
- Registration Number
- IRCT20141209020250N4
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
moderate to severe alopecia areata
Exclusion Criteria
pregnancy or lactation
receiving systemic immunosuppressive therapy during recent 3 months
severe systemic disease (eg. hepatic or renal failure )
immunosuppression
past history of severe reaction or intolerance to diphencyprone or anthralin
inability to follow regular visits or cooperation with investigators
participation in another clinical trial in recent 4 weeks
recent active sever progressive hair loss requiring systemic immunosuppressive therapy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Terminal hair regrowth rate with topical diphencyprone in comparison to the combination of topical diphencyprone with topical anthralin in patients with moderate to severe alopecia areata, based of SALT score. Timepoint: before intervention and 3 and 6 months after intervention. Method of measurement: Severity of Alopecia Tool Score.;Rate of change in Severity of Alopecia Tool score than the base value, after intervention and at the end of course of treatment. Timepoint: 3 and 6 months after treatment. Method of measurement: Severity of Alopecia Tool score.;Comparison of response time to treatment with topical diphencyprone exclusively or combination of topical diphencyprone and anthralin. Timepoint: 3 and 6 months after intervention. Method of measurement: time duration (month).
- Secondary Outcome Measures
Name Time Method Evaluation of patients' satisfaction with topical diphencyprone with and without topical anthralin at the end of the survey, using Dermatology Life Quality Index questionnaire. Timepoint: 6 months after treatment. Method of measurement: Dermatology Life Quality Index questionnaire.;Investigating side effects of treatment (eg. dermatitis , lymphadenopathy , folliculitis , urticaria and etc.). Timepoint: 3 and 6 months after treatment. Method of measurement: patient examination and history.